You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm beat analysts' revenue expectations for the quarter while its net loss was in line with predictions.
The firm has completed submissions for all three of its ePlex panels for diagnosis and management of bloodstream infections that can lead to sepsis.
Smaller multiplex molecular panels of five or fewer targets will be covered, while a determination of gastrointestinal panel coverage is expected soon.
CareDx and Invitae each had massive share-price gains last month. Exact Sciences, GenMark, and Natera also saw sizeable increases in their stock prices.
The company beat the consensus Wall Street estimate on the top line but missed it on the bottom line. It placed 39 net new ePlex analyzer during the quarter.
Month over month, the 360Dx Index beat the Dow Jones Industrial Average, the Nasdaq Composite, and the Nasdaq Biotech Index.
It is the first of three ePlex molecular multiplex panels for the diagnosis and management of bloodstream infections that can lead to sepsis.
In 2018, the company expects to place between 140 and 170 new ePlex analyzers, and an annuity per ePlex in the $100,000 to $120,000 range.
The share prices of 20 companies in the 360Dx Index rose last month, with Exact Sciences, Natera, Invitae, and NeoGenomics the biggest gainers.
Seventeen of the 25 companies in the 360Dx Index saw their shares decline last month. Invitae paced the decliners, while GenMark led the gainers.